CO2018002516A2 - Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos - Google Patents

Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos

Info

Publication number
CO2018002516A2
CO2018002516A2 CONC2018/0002516A CO2018002516A CO2018002516A2 CO 2018002516 A2 CO2018002516 A2 CO 2018002516A2 CO 2018002516 A CO2018002516 A CO 2018002516A CO 2018002516 A2 CO2018002516 A2 CO 2018002516A2
Authority
CO
Colombia
Prior art keywords
mpegs
triazin
synthase
chloro
inhibitors
Prior art date
Application number
CONC2018/0002516A
Other languages
English (en)
Spanish (es)
Inventor
Ikuo Mitani
Masaki Yamashita
Yutaro Hirono
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CO2018002516A2 publication Critical patent/CO2018002516A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CONC2018/0002516A 2015-08-17 2018-03-12 Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos CO2018002516A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015160284 2015-08-17
PCT/JP2016/073879 WO2017030115A1 (ja) 2015-08-17 2016-08-16 ヒドロキシトリアジン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
CO2018002516A2 true CO2018002516A2 (es) 2018-05-31

Family

ID=58052084

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002516A CO2018002516A2 (es) 2015-08-17 2018-03-12 Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos

Country Status (19)

Country Link
US (3) US20170057943A1 (enExample)
EP (2) EP4046991A1 (enExample)
JP (4) JP2017039714A (enExample)
KR (1) KR20180037270A (enExample)
CN (1) CN108137515B (enExample)
AR (1) AR105711A1 (enExample)
AU (1) AU2016309337B2 (enExample)
BR (1) BR112018001809A2 (enExample)
CA (1) CA2992410A1 (enExample)
CL (1) CL2018000430A1 (enExample)
CO (1) CO2018002516A2 (enExample)
IL (1) IL257559B (enExample)
MX (1) MX375283B (enExample)
PE (1) PE20180951A1 (enExample)
PH (1) PH12018500181A1 (enExample)
SG (1) SG11201800698VA (enExample)
TW (1) TWI704139B (enExample)
WO (1) WO2017030115A1 (enExample)
ZA (1) ZA201801134B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
JP2017039714A (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
US10710967B2 (en) * 2015-10-29 2020-07-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
RU2648181C1 (ru) * 2017-05-25 2018-03-22 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения нейроретинопатии вследствие тяжелой преэклампсии
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
KR20250030486A (ko) * 2022-07-06 2025-03-05 아스카 세이야쿠 가부시키가이샤 피리미딘 유도체

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EA004656B1 (ru) 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
ES2398854T3 (es) 2007-04-03 2013-03-22 E. I. Du Pont De Nemours And Company Fungicidas de benceno sustituido
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Adeka 2,4,6−トリス(ヒドロキシフェニル)−1,3,5−トリアジン化合物の製造方法
US8716474B2 (en) 2008-06-04 2014-05-06 Adeka Corporation Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) 2014-11-13 2016-05-18 东丽纤维研究所(中国)有限公司 一种拒水抗紫外纺织品及其生产方法和用途
JP2017039714A (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途

Also Published As

Publication number Publication date
BR112018001809A2 (pt) 2018-09-18
CN108137515B (zh) 2021-07-06
JP7640658B2 (ja) 2025-03-05
US12492182B2 (en) 2025-12-09
TW201718524A (zh) 2017-06-01
SG11201800698VA (en) 2018-03-28
AU2016309337B2 (en) 2021-03-04
KR20180037270A (ko) 2018-04-11
RU2018109220A (ru) 2019-09-19
JP2020193235A (ja) 2020-12-03
JP2017039714A (ja) 2017-02-23
IL257559A (en) 2018-04-30
IL257559B (en) 2021-07-29
EP3339296A1 (en) 2018-06-27
JP2024019449A (ja) 2024-02-09
CL2018000430A1 (es) 2018-08-03
MX2018002044A (es) 2018-04-13
US20210024486A1 (en) 2021-01-28
CN108137515A (zh) 2018-06-08
EP4046991A1 (en) 2022-08-24
WO2017030115A1 (ja) 2017-02-23
RU2018109220A3 (enExample) 2019-11-15
US20240076278A1 (en) 2024-03-07
US20170057943A1 (en) 2017-03-02
PH12018500181A1 (en) 2018-07-30
AR105711A1 (es) 2017-11-01
ZA201801134B (en) 2019-07-31
CA2992410A1 (en) 2017-02-23
TWI704139B (zh) 2020-09-11
AU2016309337A1 (en) 2018-02-01
MX375283B (es) 2025-03-06
JP2022163169A (ja) 2022-10-25
EP3339296A4 (en) 2019-01-23
PE20180951A1 (es) 2018-06-11

Similar Documents

Publication Publication Date Title
CO2018002516A2 (es) Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
MX2020007265A (es) Derivados de rapamicina.
CL2020002562A1 (es) (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MX2018013763A (es) Compuestos para promover crecimiento del cabello y/o inhibir o retardar perdida del cabello en humanos, y composiciones para tales usos.
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
MX376283B (es) Compuestos de imidazopiridazina.
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA201692300A1 (ru) Производные карбоксамида
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
MX389261B (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
EA202190558A1 (ru) Новые производные тиазола и их фармацевтически приемлемые соли
MX2024001441A (es) Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
NZ801355A (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии